Repurposing drugs during the COVID-19 pandemic and beyond

Affiliations

¹ Symbiosis School of Biological Sciences (SSBS) (formerly Symbiosis School of Biomedical Sciences), Symbiosis International (Deemed University), Gram-Lavale, Taluka-Mulshi Dist, Pune 412115, India.
² Symbiosis Institute of Health Sciences, Symbiosis International (Deemed University), Gram-Lavale, Taluka-Mulshi Dist, Pune 412115, India.

Editorial

Srividya Ravi et al. Pharm Pat Anal. 2021 Jan.

. 2021 Jan;10(1):9-12.

doi: 10.4155/ppa-2020-0031. Epub 2021 Jan 15.

¹ Symbiosis School of Biological Sciences (SSBS) (formerly Symbiosis School of Biomedical Sciences), Symbiosis International (Deemed University), Gram-Lavale, Taluka-Mulshi Dist, Pune 412115, India.
² Symbiosis Institute of Health Sciences, Symbiosis International (Deemed University), Gram-Lavale, Taluka-Mulshi Dist, Pune 412115, India.

No abstract available

Keywords: pandemic; patent claims; pharmaceutical industry; repurposing.

References

1. World Health Organization. WHO coronavirus disease (COVID-19) dashboard. (2020). https://covid19.who.int/
1. World Health Organization Declares COVID-19 a ‘Pandemic’. Here's what that means (2020). https://time.com/5791661/who-coronavirus-pandemic-declaration/
1. Gilead. Gilead sciences statement on request to rescind remdesivir orphan drug designation. (2020). https://www.gilead.com/news-and-press/company-statements/gilead-sciences...
1. Agrawal U, Raju R, Udwadia ZF. Favipiravir: a new and emerging antiviral option in COVID-19. Med. J. Armed Forces India 76, 370–376 (2020). - PMC - PubMed
1. Joshi S, Joshi M, Degani M. Tackling SARS-CoV-2: proposed targets and repurposed drugs. Future Med. Chem. 12(17), 1579–1601 (2020). - PMC - PubMed